Dato-DXd trumps chemo in advanced HR+/HER2– breast cancerOctober 25, 2023Breast CancerMetastatic Breast Cancer
Enfortumab vedotin/pembrolizumab hailed as new standard for upfront mUCOctober 25, 2023Genitourinary CancerPatient & Survivor Care
The sobering facts about alcohol and cancerOctober 25, 2023Patient & Survivor CareMixed TopicsBreast Cancer
Study reveals potentially unnecessary CRC screening in older adultsOctober 25, 2023Preventive CareGastroenterology
Enzalutamide improves metastasis-free survival, QoL in prostate cancerOctober 24, 2023Genitourinary Cancer
Chemo-immunotherapy good, adding a PARP inhibitor better in endometrial cancer?October 23, 2023Gynecologic CancerPatient & Survivor Care
Perioperative nivolumab improves EFS in resectable NSCLCOctober 22, 2023Lung CancerPatient & Survivor Care
ICIs improve pCR rates in early ER+/HER2– breast cancerOctober 22, 2023Breast CancerPatient & Survivor Care
Observation, not radiotherapy, after radical prostatectomyOctober 22, 2023Genitourinary CancerPatient & Survivor Care
No benefit to adding ICI to chemo in triple-negative breast cancer: studyOctober 22, 2023Breast CancerPatient & Survivor Care
